Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 6/20 | 0.72 |
| ▸ | GAA | P10253 | 5/20 | 0.72 |
| ▸ | SI | P14410 | 5/20 | 0.72 |
| ▸ | MGAM2 | Q2M2H8 | 5/20 | 0.72 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.72 |
| ▸ | FASN | P49327 | 4/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.72 |
| ▸ | IDH1 | O75874 | 4/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.72 |
| ▸ | PGAM1 | P18669 | 3/20 | 0.72 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.72 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.72 |
| ▸ | TTR | P02766 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.72 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416398 | 0.87 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL29460081 | 0.84 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL30634827 | 0.84 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL3753526 | 0.84 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL5613424 | 0.82 | NUDT1 (0.76) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL12241934 | 0.82 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL12430368 | 0.82 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL13081216 | 0.81 | MGAM (0.79) | MGAMGAASIMGAM2NUDT1 | |
| Mangostin SCHEMBL27218086 | 0.81 | MGAM (0.93) | MGAMGAASIMGAM2NUDT1 | |
| Mangostin SCHEMBL354735 | 0.79 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824442-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | Renaissance Herbs, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2007002666-A2 | PHARMACEUTICAL AND THERAPEUTIC COMPOSTIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060292255-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSSANCE HERBS INC. | 2006-12-28 | — | — | US | claimed |
| WO-2006055688-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060105069-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSANCE HERBS, INC. | 2006-05-18 | — | — | US | claimed |
| EP-3110414-B1 | XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS | UNIV DEAKIN (AU) | 2020-09-30 | — | — | EP | disclosed |
| US-10568862-B2 | Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders | DEAKIN UNIVERSITY (AU) | 2020-02-25 | — | — | US | disclosed |
| US-20160367521-A1 | XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS | DEAKIN UNIVERSITY (AU) | 2016-12-22 | — | — | US | disclosed |
| US-20160367521-A1 | XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS | DEAKIN UNIVERSITY (AU) | 2016-12-22 | — | — | US | disclosed |
| WO-2015127512-A1 | XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS | DEAKIN UNIVERSITY (AU) | 2015-09-03 | — | — | WO | disclosed |
| CN-103597071-A | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS INC | 2014-02-19 | — | — | CN | disclosed |
| EP-2689805-A1 | Oral compositions containing extracts of garcinia mangostana l. and related methods | Colgate-Palmolive Company (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2506933-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS | Colgate-Palmolive Company (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120237456-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011068814-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-1824442-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | Renaissance Herbs, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007002666-A2 | PHARMACEUTICAL AND THERAPEUTIC COMPOSTIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060292255-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSSANCE HERBS INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006055688-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060105069-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSANCE HERBS, INC. | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568862-B2 | Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders | GAP43, PMP22, ACHE | MGAM 1497/4885GAA 495/4885SI 3955/4885 |
| US-20160367521-A1 | XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS | GAP43, PMP22, ACHE | MGAM 1497/4885GAA 495/4885SI 3955/4885 |
| US-20120237456-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS | GLA, ALPP, LIPA | MGAM 84/4885GAA 9/4885SI 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.